Original articles
Effects of pemafibrate (a selective PPAR-α agonist) versus weight loss through an intensive lifestyle modification on liver enzymes, serum soluble dipeptidyl peptidase-4, and hepatic steatosis and fibrosis evaluated by FibroScan transient elastography in people with type 2 diabetes and MASLD
Kanako Kato, Teruo Jojima, Dai Tanuma, Kanako Suda, Shintaro Sakurai, Toshie Iijima, Takuya Tomaru, Isao Usui, Yoshimasa Aso
Corresponding author
Department of Endocrinology and Metabolism, Dokkyo Medical University, Mibu, Tochigi, Japan